Nick Beard appointed non-executive director at Deontics


Artificial intelligence health company adds board member to promote growth in evidence-based and personalised medicine markets in US and UK

Nick Beard

Nick Beard

Clinically-led artificial intelligence (AI) company Deontics has appointed Nick Beard as a non-executive director, adding to its growing pool of strategic health, science, and technology expertise.

Beard is a physician and former hospital chief information officer. Over a 30-year career, he has held numerous senior executive positions at leading electronic health records and clinical guidelines companies in both the US and UK. He will work closely with the Deontics executive team to help shape the future strategy of the company and the marketing of its state-of-the-art clinical pathways and decision modelling products into payer, provider and B2B healthcare IT markets.

Based in Seattle, Nick was SVP of Strategy at Milliman Care Guidelines, sold to the Hearst Corporation; CMO at the Healthy Communities Institute, sold to Xerox Corporation, and CMO and VP of health informatics and product marketing at IDX, which was sold to GE for $1.2bn.

While at IDX, Nick was the principal investigator on the SAGE project, working to develop a universal clinical pathways technology; collaborating with leading centres, Stanford University, the Mayo Clinic, the University of Nebraska and Intermountain Healthcare.

'I believe Deontics can become the technology of choice for organisations that work to disseminate clinical best practice in a way that fully leverages the spread of electronic health records,' said Beard. 'Deontics has the right technology, talent and vision of where the industry needs to go next to deliver personalised, evidence-based care.'

Sign up for your free email newsletter

This appointment is the latest milestone for the company since it spun-out of the University of Oxford, University College London and Cancer Research UK just two years ago. Deontics is already delivering new pathways for large NHS trusts, has built a lung cancer system for a global pharmaceutical company, and is supplying technology to several leading international IT companies.